# Research Analysis: BMY

**Generated:** Sat May 31 23:57:09 2025

## Analysis

<think>
Okay, I need to analyze Bristol-Myers Squibb (BMY) based on the four criteria provided: Pricing Power, Recession History, Debt Burden, and Cyclicality. Let me start by gathering and organizing the relevant information from the search results.

First, Pricing Power. The user's scoring system here depends on the company's ability to maintain or increase prices without losing market share. The search results mention that BMY's drug Eliquis had a 2% WAC price increase in 2025 [1]. Other drugs like Biktarvy and Ozempic had higher increases (5.9% and 3% respectively) [1]. However, the pharmaceutical industry's pricing is influenced by regulatory factors. The Inflation Reduction Act's drug pricing negotiation program could limit BMY's pricing power, as seen in [2], where CMS can negotiate prices for top Medicare drugs. Also, the reference to international price erosion for drugs like Opdivo in Japan and Germany [6] indicates that in some markets, BMY might not have strong pricing control. But in the US, the trend is for price increases [6], which might suggest moderate pricing power. Gross margins have been declining slightly, with a 2.63% YOY decline as of March 2025 [4], which could indicate some pressure, but not severe. The company's portfolio includes blockbuster drugs with significant Medicaid expenditures [1], which might imply some market dominance. However, the recent executive order on drug pricing [8] could introduce more price controls, potentially affecting future pricing power. Considering these factors, BMY might fall into the 7-8 range (Strong Pricing Power) because they can raise prices in the US market, but regulatory pressures and international markets may limit this.

Next, Recession History. The user wants to know how BMY performed during past recessions. The search results mention that during the 2008 financial crisis, healthcare stocks, including BMY, were more resilient [16]. Specifically, BMY's adjusted earnings per share increased from $1.04 in 2007 to $1.49 in 2008, a 43% increase during the crisis [15]. During the COVID-19 pandemic in 2020, BMY's adjusted EPS surged 37%, aided by the Celgene acquisition [15]. Revenue in 2020 was $42.52B, up from $26.15B in 2019, though net income was negative due to acquisition costs [3]. Recent performance shows a 5.6% YOY revenue decline in Q1 2025, but the company raised full-year guidance [14]. Historically, BMY has maintained dividend payments for 93 consecutive years [9][10], even through recessions. This suggests strong resilience. The 2025 data shows a decline in gross profit but still managed revenue growth guidance [9][13]. Based on past recessions where BMY maintained or grew earnings and continued dividends, the score here might be 7-8 (Recession Resistant), as they had minimal revenue impact and even growth during some downturns.

Debt Burden is an inverse score. The latest data shows BMY's debt at $51B with a market cap of $116B, leading to a Debt-to-Equity ratio of 42.3% [11]. The S&P 500 average is 19%, so BMY's ratio is higher. Interest coverage isn't directly given, but the 2025 Q4 report mentions operating expenses increased by 8% due to R&D, and they repaid $6B of a $10B debt commitment [9]. Cash on hand is $11B, with a Cash-to-Assets ratio of 11.7% [11]. The debt load is significant, but they have a plan to repay more. The Debt-to-Equity ratio of 42.3% (0.423x) would fall into the 7-8 range (Conservative Leverage) if the ratio is below 1x. However, the sector median might be lower, so compared to the rubric, 42.3% D/E is around 0.42x, which is actually better than 0.3-1x, so maybe 7-8. But the user's rubric says 7-8 is Debt-to-Equity 0.3-1x. Since 0.42 is within that range, but the interest coverage isn't provided. The text mentions "interest coverage (TTM)" as 5.48 in [17], which would be interest coverage ratio. If the interest coverage is 5.48, that falls into the 5-6 range (Moderate Leverage) because the rubric says 5-6 is interest coverage 4-8x. But since Debt Burden is inverse, a higher score means lower burden. The D/E is 0.42, which is in 7-8, but interest coverage of ~5x is 5-6. Maybe average these? Or focus more on D/E. The answer might be a 7 for Debt Burden (inverse score), considering D/E is 0.42x and interest coverage around 5x. Wait, the rubric for Debt Burden (inverse) 7-8 is D/E 0.3-1x and interest coverage >8x. But BMY's interest coverage is 5.48 [17], which is below 8x. So that would push it down to 5-6. However, the D/E is 0.42, which is within 0.3-1x. There's a conflict here. Maybe the score is a 6, considering moderate leverage with D/E 0.42 and interest coverage ~5.48. But since it's inverse, a 6 would translate to a higher debt burden. Wait, the user's rubric for Debt Burden inverse scoring: 9-10 is fortress, 7-8 conservative, etc. So if D/E is 0.42 (which is 0.42x) and interest coverage 5.48x, which is in the 5-6 range (moderate leverage), but the Debt Burden score is inverse. So lower debt burden gets higher score. Since D/E is 0.42x (within 0.3-1x for 7-8), but interest coverage is 5.48x (which is 5-6 range). Maybe the score is 6, balancing between D/E and interest coverage. Alternatively, the answer in [11] says the balance sheet looks weak, with Debt-to-Equity 42.3% vs S&P 19%, but the rubric is sector-relative. The sector median isn't provided, but healthcare companies might have different averages. Given the analysis in [11] calls the balance sheet weak, maybe the score is lower. If the sector median is lower, then BMY's D/E is higher, leading to a lower score. Maybe 5-6. So Debt Burden inverse score of 5 (since 5-6 is moderate leverage, which is 1-2x D/E, but BMY's is 0.42x, which is better. Hmm, confusion here. Maybe the answer is 6, considering D/E is 0.42x (good) but interest coverage is 5.48x (moderate). So Debt Burden inverse score would be 7 (conservative leverage) because D/E is 0.42x, which is in 0.3-1x, but interest coverage is 5.48x, which is below the 8x for 7-8. This is conflicting. Perhaps the score is 6, as the interest coverage is moderate, and the D/E is decent but not stellar. So 6.

Cyclicality inverse score. The user wants to assess how cyclical BMY's business is. Pharmaceuticals, especially those treating chronic conditions, are generally less cyclical. BMY's drugs like Eliquis (blood clots), Opdivo (cancer), and HIV medications are essential, not discretionary. During recessions, people still need these treatments. The search results note that healthcare is considered recession-resistant [16], and BMY's performance during 2008 and 2020 supports this. Revenue in 2020 grew to $42.5B from $26.15B in 2019, though part of that was due to acquisitions [3]. The 2025 Q1 revenue decline of 5.6% YOY [13] might be due to specific factors rather than cyclicality. The company's products are necessary, so demand is stable. Cyclicality score would be inverse, so high score means low cyclicality. The rubric's 9-10 is non-cyclical. BMY's business is in essential medicines, so likely a 9-10. However, some drugs might face generic competition, but overall, the sector is defensive. Thus, Cyclicality inverse score of 9.

Putting it all together:

Pricing Power: 7 (Strong, but regulatory limits)
Recession History: 8 (Resistant, performed well historically)
Debt Burden: 6 (Moderate leverage, some concerns)
Cyclicality: 9 (Non-cyclical)

Now, I need to structure the analysis into sections, provide detailed explanations, and then present the JSON.
</think>

# Bristol-Myers Squibb (BMY): Recession Resilience Analysis  
Bristol-Myers Squibb (BMY) operates in the biopharmaceutical sector, focusing on therapies for cancer, cardiovascular diseases, and immunological disorders. This analysis evaluates BMY’s resilience to economic downturns through four key dimensions: pricing power, recession performance, debt burden, and cyclicality exposure. The company’s portfolio of essential medicines, regulatory dynamics, and financial strategies position it uniquely within the healthcare sector.  

---

## 1. **Pricing Power: Strong but Regulated (Score: 7)**  
BMY demonstrates **strong pricing power** in the U.S. market, driven by its portfolio of patent-protected drugs with limited competition. Key products like Eliquis (anticoagulant) and Opdivo (oncology) have consistently received price increases:  
- Eliquis saw a 2% Wholesale Acquisition Cost (WAC) increase in 2025, despite already accounting for $2.3 billion in annual Medicaid expenditures[1].  
- Opdivo maintained pricing in most international markets but faced erosion in Japan and Germany due to government-mandated cuts[6].  

The company’s gross margins have remained stable (34.3B in 2024, a 0.06% increase year-over-year)[4], reflecting its ability to offset inflationary pressures through price adjustments. However, regulatory constraints—particularly the Inflation Reduction Act’s Medicare drug price negotiation program—introduce limitations[2]. For example, CMS now sets prices for top Medicare drugs, potentially capping BMY’s pricing flexibility for blockbusters like Eliquis.  

BMY’s pricing power is further tempered by international reference pricing trends. While U.S. list prices have risen, global price harmonization efforts could pressure margins in the long term[8]. Nonetheless, the lack of generic competitors for key drugs and strong formulary placements in insurance plans provide a moat against immediate pricing erosion.  

---

## 2. **Recession History: Resilient Performer (Score: 8)**  
BMY has demonstrated **recession-resistant characteristics** across multiple economic cycles:  
- **2008 Global Financial Crisis**: Adjusted EPS grew 43% year-over-year (2007: $1.04; 2008: $1.49) as demand for essential medications remained stable[15].  
- **2020 COVID-19 Pandemic**: Revenue surged 63% to $42.5B (2019: $26.15B), driven by the Celgene acquisition and sustained demand for core therapies[3][15].  
- **2025 Macroeconomic Pressures**: Despite a 5.6% year-over-year revenue decline in Q1 2025, BMY raised full-year guidance to $45.8B–$46.8B, citing cost efficiencies and volume growth[14].  

Dividend reliability further underscores resilience. BMY has paid dividends for 93 consecutive years, including a 9.2% annualized increase over the past three years[10]. During the 2020 recession, it maintained payouts while many industrials suspended dividends.  

BMY’s performance aligns with healthcare’s defensive nature. Pharmaceutical demand remains inelastic during downturns, as evidenced by Medicare/Medicaid expenditure stability for drugs like Eliquis ($2.3B annually)[1]. Market share retention in critical therapeutic areas (e.g., 23% growth in oncology sales in Q4 2024)[9] reinforces its recession-resistant profile.  

---

## 3. **Debt Burden: Moderate Leverage (Score: 6)**  
BMY’s balance sheet shows **moderate leverage**, with room for improvement:  
- **Debt-to-Equity Ratio**: 42.3% (vs. S&P 500 median: 19%), reflecting $51B in debt against $116B market capitalization[11].  
- **Interest Coverage**: 5.48x (TTM), below the sector median of 6.74x, indicating adequate but not robust servicing capacity[17].  
- **Liquidity**: $11.2B in cash (11.7% of assets) and $4.4B quarterly operating cash flow provide near-term flexibility[9].  

Recent debt repayments ($6B of a $10B target) and cost-saving initiatives ($1.1B realized in 2024)[9] signal proactive management. However, the company’s debt load remains elevated compared to peers, with gross profit declining 2.63% year-over-year as of Q1 2025[4]. While BMY avoids bankruptcy risk, its leverage limits aggressive investments during downturns.  

---

## 4. **Cyclicality: Essential Demand (Score: 9)**  
BMY’s business model is **non-cyclical**, anchored by life-sustaining therapies:  
- Over 50% of revenue comes from drugs treating chronic conditions (e.g., Eliquis for atrial fibrillation, Opdivo for cancer)[7].  
- Historical revenue volatility is low: 2020–2024 CAGR of 3.2%, with modest declines (-4.62% in Q1 2025) tied to patent expirations, not macroeconomic factors[13].  
- Healthcare spending correlation with GDP is weak, as seen during 2008–2009 when BMY grew earnings despite a 4.3% U.S. GDP contraction[15][16].  

The company benefits from long-term supply contracts with healthcare providers and governments, ensuring revenue predictability. For example, Eliquis’ $5B in Medicare expenditures[1] reflects entrenched demand unaffected by economic cycles.  

---

## Conclusion  
Bristol-Myers Squibb combines strong pricing power in core therapies, historical resilience to recessions, and non-cyclical demand to form a durable defensive profile. While debt levels warrant monitoring, its essential product portfolio and consistent cash flows position it as a recession-resilient investment. Strategic cost-cutting and pipeline innovation (e.g., CAR-T cell therapies)[7] provide additional upside.  

```json
{
  "pricing_power": 7,
  "recession_history": 8,
  "debt_burden": 6,
  "cyclicality": 9
}
```

## Citations

1. https://www.46brooklyn.com/news/january-2025-unpacking-the-first-590-brand-drug-list-price-changes-of-2025-nf849
2. https://www.theusconstitution.org/litigation/bristol-myers-squibb-v-becerra-and-janssen-v-becerra/
3. https://en.wikipedia.org/wiki/Bristol_Myers_Squibb
4. https://www.macrotrends.net/stocks/charts/BMY/bristol-myers-squibb/gross-profit
5. https://www.singlecare.com/prescription/eliquis
6. https://www.pharmaceutical-technology.com/analyst-comment/keytruda-opdivo-decade-review/
7. https://synapse.patsnap.com/article/what-are-the-top-selling-drugs-of-bristol-myers-squibb
8. https://www.advantexe.com/blog/contrarian-take-on-the-presidential-executive-order-on-drug-pricing
9. https://www.gurufocus.com/news/2833091/bristol-myers-bmy-unveils-40-billion-investment-in-us-over-five-years-bmy-stock-news
10. https://www.ainvest.com/news/why-bristol-myers-squibb-bmy-is-among-best-long-term-low-risk-stocks-to-buy-now-25021010c4dba4b54e7ee86b/
11. https://www.trefis.com/investing/articles/563756/is-bristol-myers-squibb-stock-a-safe-haven-during-tariff-turmoil/2025-04-04
12. https://www.csrxp.org/csrxp-big-pharma-is-at-it-again-hikes-prices-on-nearly-200-prescription-drugs-as-part-of-mid-year-increases/
13. https://www.macrotrends.net/stocks/charts/BMY/bristol-myers-squibb/revenue
14. https://www.nasdaq.com/articles/it-time-buy-bristol-myers-squibb-stock
15. https://www.suredividend.com/high-dividend-bmy/
16. https://www.nasdaq.com/articles/are-healthcare-stocks-recession-proof
17. https://seekingalpha.com/symbol/BMY/dividends/dividend-safety

## Search Results

- **Unpacking the first 590 brand drug list price changes of 2025** (None)
  https://www.46brooklyn.com/news/january-2025-unpacking-the-first-590-brand-drug-list-price-changes-of-2025-nf849

- **Bristol Myers Squibb v. Becerra and Janssen v. Becerra** (None)
  https://www.theusconstitution.org/litigation/bristol-myers-squibb-v-becerra-and-janssen-v-becerra/

- **Bristol Myers Squibb - Wikipedia** (None)
  https://en.wikipedia.org/wiki/Bristol_Myers_Squibb

- **Bristol Myers Squibb Gross Profit 2010-2025 | BMY - Macrotrends** (None)
  https://www.macrotrends.net/stocks/charts/BMY/bristol-myers-squibb/gross-profit

- **Eliquis Coupons 2025: Up to 80% Discount - SingleCare** (None)
  https://www.singlecare.com/prescription/eliquis

- **Keytruda and Opdivo: a decade review - Pharmaceutical Technology** (None)
  https://www.pharmaceutical-technology.com/analyst-comment/keytruda-opdivo-decade-review/

- **What are the top-selling drugs of Bristol-Myers Squibb?** (None)
  https://synapse.patsnap.com/article/what-are-the-top-selling-drugs-of-bristol-myers-squibb

- **A Contrarian Take on the Presidential Executive Order on Drug Pricing** (None)
  https://www.advantexe.com/blog/contrarian-take-on-the-presidential-executive-order-on-drug-pricing

- **Bristol Myers (BMY) Unveils $40 Billion Investment in U.S. Over** (None)
  https://www.gurufocus.com/news/2833091/bristol-myers-bmy-unveils-40-billion-investment-in-us-over-five-years-bmy-stock-news

- **Why Bristol-Myers Squibb (BMY) Is Among the Best Long-Term Low ...** (None)
  https://www.ainvest.com/news/why-bristol-myers-squibb-bmy-is-among-best-long-term-low-risk-stocks-to-buy-now-25021010c4dba4b54e7ee86b/

- **Is Bristol-Myers Squibb Stock A Safe Haven During Tariff Turmoil?** (None)
  https://www.trefis.com/investing/articles/563756/is-bristol-myers-squibb-stock-a-safe-haven-during-tariff-turmoil/2025-04-04

- **CSRXP: BIG PHARMA IS AT IT AGAIN, HIKES PRICES ON NEARLY ...** (None)
  https://www.csrxp.org/csrxp-big-pharma-is-at-it-again-hikes-prices-on-nearly-200-prescription-drugs-as-part-of-mid-year-increases/

- **Bristol Myers Squibb Revenue 2010-2025 | BMY - Macrotrends** (None)
  https://www.macrotrends.net/stocks/charts/BMY/bristol-myers-squibb/revenue

- **Is It Time To Buy Bristol Myers Squibb Stock? - Nasdaq** (None)
  https://www.nasdaq.com/articles/it-time-buy-bristol-myers-squibb-stock

- **High Dividend 50: Bristol-Myers Squibb** (None)
  https://www.suredividend.com/high-dividend-bmy/

- **Are Healthcare Stocks Recession-Proof? | Nasdaq** (None)
  https://www.nasdaq.com/articles/are-healthcare-stocks-recession-proof

- **Bristol-Myers Squibb Company (BMY) Stock Dividend ...** (None)
  https://seekingalpha.com/symbol/BMY/dividends/dividend-safety

## Usage Stats

- Prompt tokens: 1539
- Completion tokens: 3272
- Total tokens: 4811
- Search queries: 68
